Pampers and UNICEF Celebrate a Decade Together Helping to Save Millions of Mother’s and Babies’ Lives
29.9.2015 04:57 | Business Wire
An estimated 500,000 newborn lives have been saved and 100 million women and their newborns protected from the deadly disease, maternal and newborn tetanus, thanks to a ten-year long partnership between Pampers® and UNICEF that helped achieve this milestone.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150928006757/en/
New York, 28th September 2015. Pampers and UNICEF celebrate a decade together helping to save 100 million women and their babies. Representatives reflected on the successes of the 10 year initiative at the US Fund for UNICEF, including Yoka Brandt, UNICEF Deputy Executive Director, Celebrity Mum & Pampers UNICEF Ambassador Emma Bunton, Gerard Bocquenet, Director of Private Fundraising and Partnerships, UNICEF, Sirma Umur, VP of Baby Care, P&G and Dr. Holly Phillips, CBS News Medical Contributor and event moderator. (Photo: Business Wire)
The partners marked the tenth anniversary of their work today by celebrating the contributions of their joint effort that has helped in the elimination of maternal and newborn tetanus in 17 countries, with the success of the ‘1 Pack = 1 Vaccine’ initiative.
Long-standing spokesperson for the 1 Pack = 1 Vaccine campaign, Emma Bunton, united with Pampers & UNICEF during a global summit in New York to celebrate the progress for mothers and babies as a result of the partnership. At the event, Emma reflected on the decade-long initiative and invited everyone to mark the 10th anniversary by resolving to eliminate maternal and newborn tetanus entirely.
“Working with the people who have been instrumental in the success of this partnership, and meeting some of the mothers and babies who have enjoyed better, healthier lives as a result of the initiative has been an unforgettable experience”, said Emma Bunton.
The 1 Pack = 1 Vaccine campaign has combined two components that are essential to defeating a disease like maternal and newborn tetanus: Raising funds, and raising profile.
“The partnership between Pampers and UNICEF has resulted in much greater awareness of maternal and newborn tetanus.” said Yoka Brandt, UNICEF Deputy Executive Director. “It will take even more commitment and investment, but we can and must accelerate elimination efforts in the remaining 21 countries where the key challenge remains universal access to life saving interventions, including maternal and newborn tetanus vaccines.”
And although much has already been achieved, there is more work to be done, as maternal and newborn tetanus still threatens the lives of 71 million women and their newborns.
Sirma Umur, Pampers VP babycare E-IMEA says “We continue to partner with UNICEF to help protect the world’s babies against this deadly disease and invite everyone to join us in our 10th anniversary wish to eliminate maternal and newborn tetanus entirely.”
Tetanus is caused by bacteria that live in soil. Newborns are often infected as a result of unhygienic birth practices, such as cutting the umbilical cord with un-sterile instruments or handling it with dirty hands. Once contracted, there is no real cure. Nearly all babies who contract tetanus die, unless they receive treatment.
The true extent of the newborn tetanus death toll is not fully known, since the population at the highest risk of contracting the disease tends to live in rural areas with little or no access to health care services or education.
Newborn tetanus can be prevented through a simple vaccination given to pregnant women and women of a child-bearing age, to protect both the woman and her unborn child during this vulnerable period. Following administration of the tetanus vaccine to a pregnant mother, the antibodies pass across the placenta to her foetus.
World Health Organisation (WHO) and UNICEF recommend three appropriately spaced doses of the tetanus vaccine in order to ensure long-lasting immunity. After two doses, a woman who is vaccinated before she gives birth will be protected against the disease for three years. After three doses she will be protected for five years, and in both cases, will share her protection with her baby for the first two months of life
UNICEF promotes the rights and wellbeing of every child, in everything we do. Together with our partners, we work in 190 countries and territories to translate that commitment into practical action, focusing special effort on reaching the most vulnerable and excluded children, to the benefit of all children, everywhere. . For more information, please visit www.unicef.org .
Pampers® cares for the development of every baby around the world and continuously works in partnerships with NGOs, charity organizations, hospitals and healthcare professionals to help make a difference. Some of the many initiatives which demonstrate Pampers® ongoing commitment to vulnerable and disadvantaged babies around the world include education programmes for mothers and mothers-to-be, training schemes for physicians and nurses, and the donation of equipment for maternity wards and orphanages. Visit for more information: www.Pampers.co.uk/UNICEF
Colleen Cleary, 631-921-5320
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Altierre Strengthens Executive Team in Europe With Hiring of Guillaume Vicot and Niclas Qvist22.8.2017 12:00 | Pressemelding
Altierre Corp., a provider of the world’s highest density, ultra-low energy, long-range wireless technology and applications for the Internet of Things (IoT) market, today announced two additions to its France-based European executive team. Guillaume Vicot has joined the company as General manager, Europe, Middle East and Asia (EMEA) and Niclas Qvist has joined as Vice President, Partner management & Marketing. Vicot joins Altierre’s management team after 17 successful years in the Auto-ID industry, barcode scanning and mobile computing. He most recently served as Vice President of sales, Western Europe, for PSC / Datalogic, leader in the bar code scanning industry, where he oversaw a team of more than 100 people and developed a tactical go-to-market strategy, achieving revenue well over US$100 million. “Guillaume has many top level strategic relationships with retailers
IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11 | Pressemelding
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25 | Pressemelding
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00 | Pressemelding
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03 | Pressemelding
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom